Advax-2 formulations have demonstrated faster induction of protective immunity, induction of broadly cross-neutralizing antibodies, and long-lasting memory CD4 and CD8 T-cell responses as well as a favorable safety profile in clinical trials of COVID-19, influenza, hepatitis B, and allergy vaccines involving over 20,000 human subjects to date and is contained in a now licensed COVID-19 vaccine [16,17,18]. Here, CD8A is linked to COVID-19.